Abstract：
UNASSIGNED: Portable digital health technologies (DHTs) could help evaluate non-cognitive symptoms, but evidence to support their use in patients with dementia with Lewy bodies (DLB) is uncertain.
UNASSIGNED: 1) To describe portable or wearable DHTs used to obtain digital biomarkers in patients with DLB, 2) to assess the digital biomarkers\' ability to evaluate non-cognitive symptoms, and 3) to assess the feasibility of applying digital biomarkers in patients with DLB.
UNASSIGNED: We systematically searched databases MEDLINE, Embase, and Web of Science from inception through February 28, 2023. Studies assessing digital biomarkers obtained by portable or wearable DHTs and related to non-cognitive symptoms were eligible if including patients with DLB. The quality of studies was assessed using a modified check list based on the NIH Quality assessment tool for Observational Cohort and Cross-sectional Studies. A narrative synthesis of data was carried out.
UNASSIGNED: We screened 4,295 records and included 20 studies. Seventeen different DHTs were identified for assessment of most non-cognitive symptoms related to DLB. No thorough validation of digital biomarkers for measurement of non-cognitive symptoms in DLB was reported. Studies did not report on aspects of feasibility in a systematic way.
UNASSIGNED: Knowledge about feasibility and validity of individual digital biomarkers remains extremely limited. Study heterogeneity is a barrier for establishing a broad evidence base for application of digital biomarkers in DLB. Researchers should conform to recommended standards for systematic evaluation of digital biomarkers.
UNASSIGNED: 1) To describe portable or wearable DHTs used to obtain digital biomarkers in patients with DLB, 2) to assess the digital biomarkers\' ability to evaluate non-cognitive symptoms, and 3) to assess the feasibility of applying digital biomarkers in patients with DLB.
UNASSIGNED: We systematically searched databases MEDLINE, Embase, and Web of Science from inception through February 28, 2023. Studies assessing digital biomarkers obtained by portable or wearable DHTs and related to non-cognitive symptoms were eligible if including patients with DLB. The quality of studies was assessed using a modified check list based on the NIH Quality assessment tool for Observational Cohort and Cross-sectional Studies. A narrative synthesis of data was carried out.
UNASSIGNED: We screened 4,295 records and included 20 studies. Seventeen different DHTs were identified for assessment of most non-cognitive symptoms related to DLB. No thorough validation of digital biomarkers for measurement of non-cognitive symptoms in DLB was reported. Studies did not report on aspects of feasibility in a systematic way.
UNASSIGNED: Knowledge about feasibility and validity of individual digital biomarkers remains extremely limited. Study heterogeneity is a barrier for establishing a broad evidence base for application of digital biomarkers in DLB. Researchers should conform to recommended standards for systematic evaluation of digital biomarkers.
摘要：
■便携式数字健康技术（DHT）可以帮助评估非认知症状，但支持将其用于路易体痴呆(DLB)患者的证据尚不确定.
■1）描述用于获得DLB患者数字生物标志物的便携式或可穿戴DHT，2)评估数字生物标志物评估非认知症状的能力，3）评估在DLB患者中应用数字生物标志物的可行性。
■我们系统地搜索了MEDLINE数据库，Embase,和WebofScience从成立到2023年2月28日。如果包括DLB患者，则评估通过便携式或可穿戴DHT获得的数字生物标志物并与非认知症状相关的研究符合资格。使用基于用于观察队列和横断面研究的NIH质量评估工具的修改的检查表来评估研究质量。对数据进行了叙述性综合。
■我们筛选了4,295条记录，包括20项研究。确定了17种不同的DHT用于评估与DLB相关的大多数非认知症状。没有关于测量DLB非认知症状的数字生物标志物的彻底验证的报道。研究没有系统地报告可行性。
■关于单个数字生物标志物的可行性和有效性的知识仍然极其有限。研究异质性是建立数字生物标志物在DLB中应用的广泛证据基础的障碍。研究人员应符合数字生物标志物系统评估的推荐标准。
■1）描述用于获得DLB患者数字生物标志物的便携式或可穿戴DHT，2)评估数字生物标志物评估非认知症状的能力，3）评估在DLB患者中应用数字生物标志物的可行性。
■我们系统地搜索了MEDLINE数据库，Embase,和WebofScience从成立到2023年2月28日。如果包括DLB患者，则评估通过便携式或可穿戴DHT获得的数字生物标志物并与非认知症状相关的研究符合资格。使用基于用于观察队列和横断面研究的NIH质量评估工具的修改的检查表来评估研究质量。对数据进行了叙述性综合。
■我们筛选了4,295条记录，包括20项研究。确定了17种不同的DHT用于评估与DLB相关的大多数非认知症状。没有关于测量DLB非认知症状的数字生物标志物的彻底验证的报道。研究没有系统地报告可行性。
■关于单个数字生物标志物的可行性和有效性的知识仍然极其有限。研究异质性是建立数字生物标志物在DLB中应用的广泛证据基础的障碍。研究人员应符合数字生物标志物系统评估的推荐标准。
